Avalo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 7:35 am ET in New York. Additionally, management will join a panel discussion titled "Dermatology: AA, HS, PSO" at the Oppenheimer Innovators in I&I Summit on June 25, 2025, at 10am ET in New York. Webcasts and replays will be available on the company's investor relations website for at least 30 days.

News Market Reaction

-3.47%

1 alert

-3.47% News Effect

On the day this news was published, AVTX declined 3.47%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.

Jefferies Global Healthcare Conference 2025, New York
Fireside Chat
June 4, 2025, at 7:35 am ET

Oppenheimer Innovators in I&I Summit, New York
Panelist: “Dermatology: AA, HS, PSO”
June 25, 2025, at 10am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com 
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com 

FAQ

What investor conferences will AVTX participate in during June 2025?

Avalo Therapeutics will participate in the Jefferies Global Healthcare Conference on June 4 and the Oppenheimer Innovators in I&I Summit on June 25, 2025, both in New York.

When is Avalo Therapeutics' presentation at the Jefferies Healthcare Conference 2025?

Avalo Therapeutics will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 7:35 am ET.

What is AVTX's role at the Oppenheimer Innovators Summit 2025?

Avalo Therapeutics will participate in a panel discussion titled 'Dermatology: AA, HS, PSO' at the Oppenheimer Innovators in I&I Summit on June 25, 2025, at 10am ET.

Where can investors watch Avalo Therapeutics' conference presentations?

Live webcasts and replays will be available in the 'News / Events' section of Avalo Therapeutics' investor relations website at https://ir.avalotx.com for at least 30 days.